An Observational Study of Musculoskeletal Pain Among Patients Receiving Bisphosphonate Therapy

Caplan, Liron; Pittman, Cory B.; Zeringue, Angelique; Scherrer, Jeffrey F.; Wehmeier, Kent R.; Cunningham, Francesca; Eisen, Seth A.; McDonald, Jay R.

doi:10.4065/mcp.2009.0492

Cited by 30 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Caplan and colleagues [37] found an association of BP exposure and MSKP (RR=1.22; 95% 1.04, 1.44). They also found that female sex, depression, anxiety, comorbidity score, and the presence of a rheumatic disease are associated with a greater risk of a diagnosis of diffuse MSKP.…”

Section: Musculoskeletal Painmentioning

confidence: 95%

“…They also found that female sex, depression, anxiety, comorbidity score, and the presence of a rheumatic disease are associated with a greater risk of a diagnosis of diffuse MSKP. In elderly patients at high risk of osteoporotic fractures, BP prescription does not appear to be associated with a statistically significant risk of subsequent MSKP diagnoses [37].…”

Section: Musculoskeletal Painmentioning

confidence: 99%

See 1 more Smart Citation

Safety issues and adverse reactions with osteoporosis management

Rossini¹,

Adami²,

Adami³

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

The safety profile of most available drugs for the treatment of osteoporosis is well defined and the most serious adverse events are either rare or predictable. Osteoporosis treatment is a favorable choice in patients at moderate-high risk of fracture, while in patients at low risk pharmacological prevention should involve consideration of the balance between the beneficial effects of treatment, the probability of adverse effects and costs.

show abstract

Section: Musculoskeletal Painmentioning

confidence: 95%

Section: Musculoskeletal Painmentioning

confidence: 99%

Safety issues and adverse reactions with osteoporosis management

Rossini¹,

Adami²,

Adami³

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…Bisphosphonates reduce vertebral fractures risk and increase BMD. Non-vertebral hip fractures are also effectively reduced by some of these bisphosphonates (Wynn, 2005;Caplan et al, 2010). Alendronate, being associated with increased BMD and fracture risk reduction, is extensively recommended as a drug for treatment of postmenopausal osteoporosis (Black et al, 2000).…”

Section: Bone Resorptive Agentsmentioning

confidence: 99%

Marine Natural Products: New Avenue in Treatment of Osteoporosis

Chaugule¹,

Indap²,

Chiplunkar

2017

Front. Mar. Sci.

View full text Add to dashboard Cite

Bone metabolism is a physiological process that maintains the skeletal integrity and bone functions. Skeletal integrity is always balanced by two key cell types-bone resorbing osteoclasts and bone-forming osteoblasts. Imbalance between generation and function of osteoclasts and osteoblasts often leads to pathological conditions such as osteoporosis, osteopetrosis, Paget's disease. Osteoporosis is one of the most common age-related diseases characterized by decreased bone mineral density and microarchitectural deterioration. Current therapies are indeed effective in preventing bone loss but are also followed by side effects. Since many years, marine organisms have been considered as a good source of bioactive molecules or compounds with potential pharmaceutical properties. Marine Natural Products (MNPs) derived from various marine resources such as marine cyanobacteria, dinoflagellates, algae, sponges, soft corals, molluscs, fishes, and mangroves had shown profound effect on bone metabolism through inhibiting osteoclastogenesis and up-regulating osteoblastogenesis via modulating RANK/RANKL/OPG pathway. Amongst the pre-clinically investigated MNPs for management of osteoporosis, very few are under phase I clinical trials. This review discusses the currently available pharmacological drugs and there major health concern in osteoporosis treatment. It further gives an insight into various marine resources and marine-derived bioactive products, depicting their mechanism of action, functional role, and how these can be exploited for the treatment of osteoporosis.

show abstract

“…[23] Not only is there no known pathophysiology or causal relationship for bisphosphonate-associated musculoskeletal pain, but also, bisphosphonate use has been shown to relieve bone pain. [23] Not only is there no known pathophysiology or causal relationship for bisphosphonate-associated musculoskeletal pain, but also, bisphosphonate use has been shown to relieve bone pain.…”

Section: Y and Atrial Fibrillation Are Unclearmentioning

confidence: 99%